Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

45.78
+0.83001.85%
Volume:485.19K
Turnover:22.43M
Market Cap:1.27B
PE:-15.92
High:47.86
Open:44.56
Low:43.90
Close:44.95
52wk High:47.86
52wk Low:12.21
Shares:27.69M
Float Shares:14.25M
Volume Ratio:1.27
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8757
EPS(LYR):-5.1170
ROE:-308.02%
ROA:-4.23%
PB:-43.09
PE(LYR):-8.95

Loading ...

AnaptysBio Halts Rosnilimab Ulcerative Colitis Trial After Missing Phase 2 Endpoints

Reuters
·
Nov 10

AnaptysBio Inc - Update on Rosnilimab in Ra Expected in H1 2026

THOMSON REUTERS
·
Nov 10

AnaptysBio Inc - Uc Trial Discontinued, Savings of at Least $10 Mln

THOMSON REUTERS
·
Nov 10

AnaptysBio Inc - Rosnilimab Fails to Meet Primary Endpoint in Uc Trial

THOMSON REUTERS
·
Nov 10

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

THOMSON REUTERS
·
Nov 10

Truist Securities Adjusts AnaptysBio Price Target to $36 From $20, Maintains Hold Rating

MT Newswires Live
·
Nov 10

AnaptysBio Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 05

AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales

Reuters
·
Nov 05

BRIEF-AnaptysBio Q3 Net Income USD 15.113 Million

Reuters
·
Nov 05

AnaptysBio Inc : Leerink Partners Raises Target Price to $62 From $51

THOMSON REUTERS
·
Oct 29

AnaptysBio Reports Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

Reuters
·
Oct 29

AnaptysBio Inc - Rosnilimab Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Oct 29

AnaptysBio Inc - Rosnilimab Shows Efficacy in Ra With Cdai Remission

THOMSON REUTERS
·
Oct 29

Anaptys Announces New Positive Phase 2B Trial Results for Rosnilimab in Rheumatoid Arthritis at Acr Late-Breaking Oral Presentation

THOMSON REUTERS
·
Oct 29

Wedbush Raises Price Target on AnaptysBio to $70 From $45, Keeps Outperform Rating

MT Newswires Live
·
Oct 15

AnaptysBio price target raised to $70 from $45 at Wedbush

TIPRANKS
·
Oct 15

U.S. RESEARCH ROUNDUP-Applovin, Caterpillar, ESAB

Reuters
·
Oct 14

AnaptysBio Inc : Piper Sandler Raises Target Price to $72 From $57

THOMSON REUTERS
·
Oct 14

AnaptysBio to Present Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at ACR Convergence 2025

Reuters
·
Oct 13

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2B Data for Rosnilimab in Rheumatoid Arthritis at Upcoming Acr Convergence 2025

THOMSON REUTERS
·
Oct 13